Pancreatic Cancer Pipeline Insights

DelveInsight reports that over 290 key companies are actively engaged in developing more than 300 therapies for the treatment of pancreatic cancer.

Pancreatic Cancer Overview:

Pancreatic cancer is a malignant condition that begins in the pancreas, an abdominal organ situated behind the stomach. While it most often develops from pancreatic intraepithelial neoplasia (PanIN), it can also originate from larger precursor lesions, such as intraductal papillary mucinous neoplasms (IPMNs) and mucinous cystic neoplasms. The disease advances through abnormal autocrine and paracrine signaling, which fuels tumor growth, invasion, and metastasis.

In addition, pancreatic cancer is marked by metabolic dysregulation and resistance to growth-inhibitory pathways. A notable example is the disruption of TGFβ signaling, which normally acts as a tumor suppressor but, in this case, promotes cancer progression by accelerating tumor growth and metastasis. This effect occurs through paracrine interactions within the tumor microenvironment and direct activation of signaling pathways such as MAPK, SRC, and AKT. Moreover, TGFβ stimulates WNT7B expression via SMAD4-dependent mechanisms, further enhancing pancreatic cancer cell proliferation.

Request for a detailed insights report on Pancreatic Cancer pipeline insights

“Pancreatic Cancer Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Pancreatic Cancer Therapeutics Market.

Key Takeaways from the Pancreatic Cancer Pipeline Report

• DelveInsight’s report on the Pancreatic Cancer pipeline highlights a dynamic landscape, with over 290 active companies developing more than 300 therapies aimed at treating the disease. Leading players in this space include ERYtech Pharma, Jiangsu HengRui Medicine Co., Ltd., FibroGen, Novartis AG, AB Science, Eleison Pharmaceuticals, Cornerstone Pharmaceuticals, Panbela Therapeutics, Taiho Pharmaceutical Co., Ltd., Rain Oncology, Redx Pharma Plc, Eli Lilly and Company, Jazz Pharmaceuticals, Immodulon Therapeutics Ltd, GSK, Merck Sharp & Dohme LLC, Roche, Helsinn Healthcare SA, DEKA Biosciences, Senhwa Biosciences, Cue Biopharma, Carisma Therapeutics Inc., ChemoCentryx, Boehringer Ingelheim, Bicara Therapeutics, Arcus Biosciences, Mainline Biosciences, Beijing Imunopharm Technology Co., Ltd., TriSalus Life Sciences, Ono Pharmaceutical, Exelixis, Wellmaker Bio, Pionyr Immunotherapeutics, Ability Pharmaceuticals SL, A2 Biotherapeutics, Klus Pharma Inc., Nelum Corp, Crystal Genomics Inc., Elicio Therapeutics, Turning Point Therapeutics, Immuneering Corporation, pHion Therapeutics Ltd., AC BioScience, TheraVectys, Opna Bio, Cytuvax, Eureka Therapeutics, and several others. These companies are actively exploring novel drugs to advance pancreatic cancer treatment.

• Notable therapies currently in various stages of development include Pamrevlumab, Devimistat, Masitinib, SBP-101, TAS-102, RAIN-32, IMX-110, and more.

• In December 2024, the FDA approved Merus NV’s therapy, Bizengri, for specific lung and pancreatic cancers associated with NRG1 gene fusions. Bizengri works by blocking the interaction between the HER3 protein and the NRG1 gene, thereby preventing tumor growth. Clinical trial results were promising, showing tumor reduction or complete eradication in 40% of pancreatic cancer patients.

Pancreatic Cancer Pipeline Analysis

The report provides insights into:

• The report provides detailed insights into the key companies that are developing therapies in the Pancreatic Cancer Market.

• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pancreatic Cancer treatment.

• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Pancreatic Cancer market.

Download our free sample page report on Pancreatic Cancer pipeline insights

Pancreatic Cancer Emerging Drugs

• Pamrevlumab: FibroGen

• Devimistat: Cornerstone Pharmaceuticals

• Masitinib: AB Science

• SBP-101: Panbela Therapeutics

• TAS-102: Taiho Pharmaceutical Co., Ltd.

• RAIN-32: Rain Oncology

• IMX-110: Immix Biopharma

Pancreatic Cancer Companies

Approximately 290 companies are engaged in developing therapies for pancreatic cancer, with FibroGen leading the field with a drug candidate currently in Phase III clinical trials.

DelveInsight’s report covers around 300+ products under different phases of clinical development like

• Late stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) along with the details of

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

Pancreatic Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous

• Subcutaneous

• Oral

• Intramuscular

Pancreatic Cancer Products have been categorized under various Molecule types such as

• Monoclonal antibody

• Small molecule

• Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Pancreatic Cancer Therapies and Key Companies: Pancreatic Cancer Clinical Trials and advancements

Pancreatic Cancer Pipeline Therapeutic Assessment

• Pancreatic Cancer Assessment by Product Type

• Pancreatic Cancer By Stage

• Pancreatic Cancer Assessment by Route of Administration

• Pancreatic Cancer Assessment by Molecule Type

Download Pancreatic Cancer Sample report to know in detail about the Pancreatic Cancer treatment market @ Pancreatic Cancer Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. Pancreatic Cancer Current Treatment Patterns

4. Pancreatic Cancer – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Pancreatic Cancer Late-Stage Products (Phase-III)

7. Pancreatic Cancer Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Pancreatic Cancer Discontinued Products

13. Pancreatic Cancer Product Profiles

14. Pancreatic Cancer Key Companies

15. Pancreatic Cancer Key Products

16. Dormant and Discontinued Products

17. Pancreatic Cancer Unmet Needs

18. Pancreatic Cancer Future Perspectives

19. Pancreatic Cancer Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Pancreatic Cancer Pipeline Reports Offerings

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/